The detection and diagnosis of Niemann-Pick disease type C
Activity information
Release Date: August 29, 2026 · Expiration Date: August 29, 2027
Activity Overview
This case-based educational program is designed to improve clinician competence in the early recognition and diagnosis of Niemann–Pick disease type C (NPC). Through two interactive virtual patient simulations based on real-world diagnostic scenarios, participants will learn to identify age-dependent clinical red flags, differentiate NPC from common neurologic and psychiatric mimics, apply contemporary diagnostic pathways, interpret biomarker and genetic testing results, and recognize the diagnostic significance of ocular motor abnormalities such as vertical supranuclear saccade palsy. The activity aims to reduce diagnostic delay and support earlier referral and multidisciplinary evaluation of children and adolescents with suspected NPC.
Target Audience
This activity is designed for an audience of Physicians.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
• Recognize age-dependent NPC red flags in early childhood, including unexplained splenomegaly, developmental concerns, progressive gait or coordination changes, and cataplexy-like events
• Differentiate NPC from common pediatric mimics
• Apply current diagnostic pathways for suspected pediatric NPC, including appropriate selection and sequencing of biomarker testing and confirmatory genetic evaluation to reduce time to diagnosis
• Evaluate and interpret challenging diagnostic results in pediatric NPC
• Implement practice changes to enable earlier identification and referral, including when to escalate testing, coordinate multidisciplinary evaluation, and initiate longitudinal monitoring to improve outcomes
• Recognize the diagnostic significance of ocular motor abnormalities and understand when their presence should prompt NPC evaluation
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at ketrea@akhcme.com.
https://akhcme.com/content/detection-and-diagnosis-niemann-pick-type-c
Credit Claim Instructions
1. Click the claim link
2. Login or Create an account in the system. (All 1st time users required to create an account)
Once complete, the course will appear in your 'Pending Activities' list, found under the 'Activities' tab on your profile page (upper right-hand corner).
3. Proceed to Register/Take Course Tab to complete the Course Evaluation & Certificate steps for the activity.
4. Click get started
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Orakle LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support
This activity is supported from an independent medical education grant from Zevra Therapeutics.
Disclosures
| Name | Relationship | Commercial Interest |
|---|---|---|
| Barbara Burton MD (faculty) | Speaker | Biomarin, Zevra |
| Barbara Burton MD (faculty) | Consultant | Alltrna, Applied Therapeutics, Chiesi, Denali, JCR Pharma, Moderna, Ultragenyx, Uniqure |
| Caroline Hastings MD (faculty) | Consultant | Azafaros, Zevra, IntraBio, Cyclo Therapeutics |
| Dorothy Caputo, MA, BSN, RN - President | N/A | Nothing to disclose |
| Rebecca Lakowski, RN (planner/reviewer) | N/A | Nothing to disclose |
| AKH Inc Staff and Planners | N/A | Nothing to disclose |
| Orakle LLC Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
Pre-test
Answered before any case content is shown · answers are recorded, feedback follows the post-test.
A short professional profile and one question. Your answers power the outcome analysis for this activity; they are never used to judge you individually.
Pre-test · Question 1 of 1
According to the 2025 Consensus Clinical Management Guidelines for Niemann–Pick disease type C, which of the following represents the most appropriate diagnostic approach when NPC is clinically suspected in a child or adolescent with progressive neurological symptoms?
Introduction
History of Present Illness
Welcome. Your patient today is Daniel, a 15-year-old boy referred for evaluation of progressive cognitive and behavioral decline associated with episodic staring spells and abnormal eye movements.
Over the past 18 months, Daniel has experienced worsening concentration, declining academic performance, emotional withdrawal, and episodes of inappropriate laughter and irritability. His parents describe intermittent “blank spells” during which he suddenly stops speaking and stares for several seconds before recovering immediately. Initial psychiatric assessment suggested attention-deficit/hyperactivity disorder (ADHD), and stimulant therapy was initiated; however, despite dose escalation, his symptoms continued to progress without meaningful improvement. An electroencephalogram (EEG) demonstrated mild nonspecific generalized slowing without definite epileptiform discharges. Although this finding did not confirm epilepsy, it also did not exclude seizure activity, particularly given Daniel’s ongoing episodic staring spells and progressive neurological symptoms.
More recently, Daniel has developed subtle dysarthria, intermittent dystonic posturing of the hands, and increasing difficulty tracking objects visually, particularly when looking upward. Ophthalmologic assessment documented impaired vertical saccades, with Daniel compensating by moving his head rather than his eyes. Given the progressive neurological features, poor response to ADHD treatment, and abnormal ocular findings, Daniel has now been referred to you for further evaluation.
Physical examination is notable for mildly slowed speech with occasional subtle dysarthria. Mild intermittent dystonic posturing of the hands is observed during fine motor tasks. Daniel is alert and oriented, and his strength, muscle tone, coordination, sensation, reflexes, and gait are otherwise normal.
Given the progressive neurological features, poor response to ADHD treatment, and abnormal ocular findings, you begin to question whether ADHD adequately explains Daniel’s presentation. Before proceeding with laboratory investigations, you decide to obtain a more detailed developmental and family history from Daniel’s mother.
Consultation
Ask the patient — choose a question to play the interview.
Full transcripts below
Transcript · Ask about Daniel’s family history
Physician: Has anyone else in the family had neurological or psychiatric problems?
Mother: No, none that we’re aware of.
Mother: Not really. My father developed dementia in his seventies.
Physician: Anyone with symptoms like Daniel’s at a young age?
Mother: No, nothing like this.
Physician: Any relatives with seizures, movement problems, or learning difficulties?
Transcript · Explore Daniel’s ADHD diagnosis
Physician: How did Daniel respond to the ADHD medication?
Mother: Honestly, we didn’t notice much improvement at all.
Physician: Did his concentration improve at school?
Mother: No, his grades kept getting worse despite increasing the dose.
Physician: Any side effects from the medication?
Mother: He became quieter and more withdrawn, but the staring spells continued.
Physician: Did the medication help the unusual eye movement symptoms?
Mother: No, if anything, those became more noticeable over time.
Physician: ADHD alone would not usually explain progressive speech changes or abnormal eye movements.
Mother: That’s what’s been worrying us. It feels like something else is going on.
Physician: The lack of response to stimulant therapy and the progression of symptoms suggest we should investigate for an underlying neurological condition.
Tests
Select appropriate tests for the patient — order and sequence are part of the exercise.
Brain magnetic resonance imaging (MRI)
Detailed oculomotor assessment
Whole exome/genome sequencing
Diagnoses
Select the best diagnosis.
Your first answer is recorded before any feedback is shown — commit to the classification you would act on.
Would you like to change your diagnosis?
Your first answer stays on the record either way; a revision is recorded separately.
Existing Diagnoses
| Name | Start date | End date |
|---|---|---|
| Schizophrenia | … | Ongoing |
Post-test
The same two questions you answered before the case — now with full feedback. A score of 70% or better is required for the certificate.
Post-test · Question 1 of 1
According to the 2025 Consensus Clinical Management Guidelines for Niemann–Pick disease type C, which of the following represents the most appropriate diagnostic approach when NPC is clinically suspected in a child or adolescent with progressive neurological symptoms?
Your details
Needed to issue your certificate and send your enduring materials.
Please confirm how we should address you and where to send your certificate and downloadable resources. These details go only to Orakle and AKH for accreditation and delivery — never to the activity's supporter.
All three fields are required — email must be valid
Case Review
Daniel’s case highlights how NPC can initially mimic more common adolescent neurological and psychiatric disorders, including ADHD and epilepsy. His early symptoms—declining concentration, behavioral change, staring spells, and academic deterioration—made the initial ADHD diagnosis understandable, particularly in the absence of obvious systemic findings such as hepatosplenomegaly or cerebellar ataxia (both of which were absent in this case). Similarly, the intermittent staring episodes and nonspecific EEG slowing created a reasonable concern for seizure-related pathology.
However, the key clinical lesson is that progressive neurological symptoms and the emergence of objective neurological findings should prompt reconsideration of the original diagnosis. Although not all patients with ADHD respond adequately to stimulant therapy, Daniel continued to demonstrate progressive cognitive and behavioral decline despite treatment. The subsequent development of dysarthria, dystonic posturing, and especially VSGP represented important neurological “red flag” findings that are not explained by uncomplicated ADHD and warranted further investigation for an underlying neurodegenerative disorder.
Careful reassessment of the diagnosis, combined with targeted neurological examination and metabolic investigation, ultimately revealed elevated pathogenic NPC1 variants, confirming juvenile-onset NPC. This case emphasizes the importance of revisiting initial assumptions when the clinical course becomes atypical, progressive, or treatment-resistant, particularly in adolescents with evolving neuropsychiatric symptoms.
Neurological Features of NPC14
Strong Indicators of NPC
VSGP (impaired voluntary vertical eye movements)
VSGP is one of the most characteristic neurological manifestations of NPC and is observed in the majority of affected individuals. It is characterized by impaired voluntary vertical eye movements, particularly affecting rapid and coordinated upward and downward gaze. Although VSGP is often among the earliest detectable neurological signs of NPC, it may be subtle initially and is frequently underrecognized in clinical practice or by relatives.
Early manifestations typically involve slowing or limitation of vertical saccadic eye movements during late childhood or adolescence. As the disease progresses, horizontal saccades may also be affected. Patients commonly compensate for impaired vertical gaze by moving their head rather than their eyes when tracking objects.
Assessment for VSGP should include examination of:
- smooth pursuit eye movements—the ability to continuously track a moving target smoothly;
- saccades—rapid voluntary eye movements between fixation points; and
- vergence movements—coordinated inward and outward eye movements required to maintain focus on objects at different distances.
Vertical supranuclear saccade palsy (VSSP) (impaired rapid vertical eye movements)
VSSP is an early ocular motor abnormality frequently associated with NPC. It affects the ability to perform rapid voluntary vertical eye movements (saccades), particularly in the upward and downward directions. VSSP often precedes the development of more generalized VSGP and may represent one of the earliest neurological manifestations of NPC.
Clinical assessment for VSSP involves evaluating the patient’s ability to rapidly shift gaze between fixed visual targets. Early findings may include slowed, delayed, or hypometric vertical saccades, while smooth pursuit movements can initially remain relatively preserved.
Gelastic cataplexy (emotion-triggered transient loss of muscle tone)
Gelastic cataplexy is a characteristic but underrecognized neurological manifestation of NPC. It is defined by brief episodes of sudden muscle tone loss triggered by emotional stimuli, most commonly laughter, without associated loss of consciousness.
Episodes may involve the neck, jaw, facial muscles, or lower limbs, resulting in transient head drops, jaw slackening, knee buckling, or sudden falls. Symptoms are typically short-lived, with rapid spontaneous recovery.
Evaluation for gelastic cataplexy relies primarily on detailed clinical history, particularly identification of recurrent emotionally triggered “drop attacks” or transient postural collapse occurring in the absence of impaired awareness or postictal symptoms.
Moderate Indicators of NPC
Ataxia (impaired coordination and balance)
Ataxia is a common neurological manifestation of NPC and is characterized by impaired coordination, gait instability, clumsiness, and frequent falls. Symptoms may emerge during late childhood or adolescence and typically progress over time, affecting gait, fine motor function, speech, and balance.
In milder or early-stage disease, affected individuals may appear unusually cautious during movement, avoid running, walk more slowly than peers, or demonstrate subtle difficulty with coordinated hand movements.
Clinical assessment of ataxia may include:
- 10-meter walk test—evaluates gait speed and walking pattern over a defined distance;
- tandem gait assessment—evaluates balance and coordination during heel-to-toe walking; and
- standardized ataxia rating scales, including:
- International Cooperative Ataxia Rating Scale
- Brief Ataxia Rating Scale, and
- Scale for the Assessment and Rating of Ataxia.
These tools assist in quantifying disease severity and monitoring neurological progression over time.
Dysarthria (speech impairment due to impaired motor control)
Dysarthria is a frequent neurological feature of NPC and is characterized by slurred, slowed, or poorly articulated speech resulting from impaired control of the muscles involved in speech production, including the tongue, lips, jaw, and palate.
Affected individuals may demonstrate reduced speech clarity, altered speech rhythm, abnormal vocal volume, or difficulty controlling pitch and tone. Dysarthria in NPC commonly occurs alongside other neurological manifestations such as ataxia and dystonia, reflecting progressive involvement of motor control pathways.
Assessment of dysarthria may include:
- Frenchay Dysarthria Assessment—evaluates speech motor function and articulation abnormalities; and
- Neurological imaging studies—performed to investigate associated neurodegenerative or structural abnormalities contributing to speech dysfunction.
Dysphagia (difficulty swallowing)
Dysphagia is an important neurological manifestation of NPC and may develop as the disease progresses. Early symptoms can include difficulty swallowing liquids, prolonged eating time, coughing during meals, or choking episodes.
Progressive dysphagia increases the risk of aspiration, recurrent lower respiratory tract infections, aspiration pneumonia, dehydration, and malnutrition. In more advanced disease, impaired swallowing and reduced airway protection can become major contributors to respiratory morbidity, reduced quality of life, and disease-related complications.
Assessment of dysphagia may include:
- Videofluoroscopic swallow study—dynamic radiographic evaluation of swallowing function during ingestion of liquids and solids;
- fiberoptic endoscopic evaluation of swallowing—endoscopic assessment of pharyngeal swallowing and aspiration risk; and
- Clinical swallowing assessment—bedside evaluation of feeding, swallowing safety, and oral motor function performed by speech-language therapists or dysphagia specialists.
Early recognition and monitoring of dysphagia are important to reduce aspiration-related complications and support nutritional management. As swallowing function declines, enteral feeding support may become necessary. Gastrostomy tubes are frequently considered in patients who cannot swallow safely or who are unable to maintain adequate nutrition, hydration, or weight through oral intake alone.
Dystonia (involuntary muscle contractions and abnormal posturing)
Dystonia is a recognized neurological manifestation of NPC, particularly in adolescent- and adult-onset disease. It is characterized by sustained or intermittent involuntary muscle contractions resulting in abnormal movements, repetitive twisting motions, or abnormal posturing affecting areas such as the hands, neck, face, or lower limbs.
Symptoms may fluctuate in severity and can interfere with fine motor tasks, gait, speech, and daily activities. In NPC, dystonia often occurs alongside other progressive neurological features, including dysarthria, cognitive decline, and ocular motor abnormalities.
Clinical evaluation of dystonia primarily involves a detailed neurological examination assessing muscle tone, posture, involuntary movements, and task-specific motor abnormalities.
Other Indicators of NPC
Additional Neurological Features That May Raise Suspicion for NPC
Spasticity (progressive muscle stiffness and increased tone)
Spasticity is characterized by gradually increasing muscle stiffness and resistance to movement resulting from upper motor neuron dysfunction. Symptoms may progress slowly over time and can contribute to gait impairment, reduced mobility, muscle tightness, and difficulty performing coordinated movements.
Clinical assessment includes neurological examination, evaluating muscle tone, reflexes, range of motion, and motor function.
Hypotonia (reduced muscle tone)
Hypotonia refers to decreased muscle tone resulting in reduced resistance to passive movement and a “floppy” appearance, particularly in infants and young children. Affected individuals may demonstrate poor posture, delayed motor development, reduced strength, or difficulty maintaining sitting and standing positions.
Assessment involves neurological and developmental examination, evaluating muscle tone, posture, strength, and motor milestones.
Delayed developmental milestones (developmental delay and cognitive impairment)
Children with NPC may demonstrate delayed acquisition of developmental milestones, including speech, language, and motor skills. Over time, developmental delay may evolve into progressive cognitive impairment, learning difficulties, or intellectual decline.
Evaluation typically includes developmental screening, neuropsychological assessment, and formal cognitive testing where appropriate. Educational and vocational support should also be considered, including individualized educational plans, school accommodations, and workplace or vocational program modifications to help maintain cognitive, social, and physical participation. As the disease progresses, increasing cognitive and physical impairment may significantly affect academic achievement, employment, independence, and activities of daily living, and some individuals may ultimately be unable to continue formal education or employment.
Seizures (partial or generalized epileptic events)
Seizures may occur in individuals with NPC, particularly in late-infantile and juvenile-onset disease. Seizure types may include focal (partial) or generalized events and can present with staring episodes, involuntary movements, altered awareness, or convulsive activity. In some patients, seizures may become difficult to control despite multiple antiseizure therapies.
Assessment generally includes neurological evaluation, EEG, and neuroimaging studies, where clinically indicated.
Myoclonus (sudden involuntary muscle jerks)
Myoclonus refers to brief, shock-like involuntary muscle jerks affecting an individual muscle or group of muscles. Movements are typically abrupt, irregular, and unpredictable in timing and distribution.
Clinical evaluation includes neurological examination assessing the frequency, distribution, triggers, and functional impact of involuntary movements, with electrophysiological testing considered in selected cases.
Psychiatric Symptoms of NPC
Psychiatric and Neurocognitive Features Associated With NPC
Presenile cognitive decline and dementia (progressive decline in cognitive function occurring before older adulthood)
Individuals with NPC may develop progressive cognitive impairment involving deterioration in memory, executive function, attention, abstract reasoning, and daily functioning. Early-onset cognitive decline may emerge during adolescence or adulthood and can progress to presenile dementia.
Assessment typically involves formal cognitive evaluation using standardized neuropsychological tools, such as the Mini-Mental State Examination or broader neurocognitive testing batteries, alongside neurological and functional assessment.
Psychotic symptoms (disturbances in perception, thought content, or reality testing)
Psychiatric manifestations of NPC may include psychotic symptoms such as hallucinations, paranoid delusions, delusional thinking, social withdrawal, agitation, aggressive behavior, or self-injurious behavior. In some individuals, psychiatric symptoms may precede overt neurological findings and initially lead to a primary psychiatric diagnosis.
As neurological abnormalities emerge—including impaired vertical eye movements, dysarthria, ataxia, dystonia, or dysphagia—reconsideration of an underlying neurodegenerative disorder such as NPC becomes important.
Clinical psychiatric assessment should evaluate symptom progression, behavioral changes, psychosis severity, cognitive decline, and associated neurological features.
Treatment-resistant psychiatric symptoms (psychiatric manifestations with poor response to standard therapy)
Individuals with NPC may present with psychiatric symptoms that respond poorly or incompletely to conventional psychiatric treatments, including antipsychotic medications, antidepressants, or behavioral interventions.
Progressive symptoms despite optimized psychiatric management should prompt reassessment for an underlying neurological or metabolic disorder, particularly when accompanied by cognitive decline or abnormal neurological examination findings.
Other psychiatric disorders (neuropsychiatric conditions associated with NPC)
A range of psychiatric disorders has been reported in individuals with NPC, including schizophrenia-spectrum disorders, depression, anxiety, mood instability, and behavioral dysregulation.
These symptoms may occur in isolation early in the disease course, contributing to delayed diagnosis before more characteristic neurological manifestations become apparent.
Disruptive and aggressive behavior in childhood or adolescence (behavioral dysregulation affecting social and educational functioning)15
Children and adolescents with NPC may exhibit irritability, impulsivity, emotional dysregulation, aggression, oppositional behaviors, or socially inappropriate behavior. Difficulties in school performance, interpersonal relationships, and adherence to rules may become increasingly apparent over time.
Behavioral changes are often initially attributed to primary psychiatric or developmental disorders before progressive neurological features emerge.
- T.Hiwot, F. D.Porter, T.Bremova-Ertl, et al., “2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C,” Journal of Inherited Metabolic Disease49, no. 3 (2026): e70185, https://doi.org/10.1002/jimd.70185. Open source ↗
- T.Hiwot, F. D.Porter, T.Bremova-Ertl, et al., “2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C,” Journal of Inherited Metabolic Disease49, no. 3 (2026): e70185, https://doi.org/10.1002/jimd.70185. Open source ↗
- T.Hiwot, F. D.Porter, T.Bremova-Ertl, et al., “2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C,” Journal of Inherited Metabolic Disease49, no. 3 (2026): e70185, https://doi.org/10.1002/jimd.70185. Open source ↗
- Yang K, Quiroz V, Tam A, Srouji R, Villanueva X, Amarales C, Ebrahimi-Fakhari D. Juvenile-onset Huntington's disease - Spectrum and evolution of presenting movement disorders. Ann Clin Transl Neurol. 2024 Oct;11(10):2805-2810. doi: 10.1002/acn3.52193. Epub 2024 Sep 6. PMID: 39239850; PMCID: PMC11514935. Open source ↗
- T.Hiwot, F. D.Porter, T.Bremova-Ertl, et al., “2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C,” Journal of Inherited Metabolic Disease49, no. 3 (2026): e70185, https://doi.org/10.1002/jimd.70185. Open source ↗
- T.Hiwot, F. D.Porter, T.Bremova-Ertl, et al., “2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C,” Journal of Inherited Metabolic Disease49, no. 3 (2026): e70185, https://doi.org/10.1002/jimd.70185. Open source ↗
- Uy CE, Binks S, Irani SR. Autoimmune encephalitis: clinical spectrum and management. Pract Neurol. 2021 Oct;21(5):412-423. doi: 10.1136/practneurol-2020-002567. Epub 2021 Jun 9. PMID: 34108243; PMCID: PMC8461404. Open source ↗
- T.Hiwot, F. D.Porter, T.Bremova-Ertl, et al., “2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C,” Journal of Inherited Metabolic Disease49, no. 3 (2026): e70185, https://doi.org/10.1002/jimd.70185. Open source ↗
- European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson's disease. J Hepatol. 2025 Feb 22:S0168-8278(24)02706-5. doi: 10.1016/j.jhep.2024.11.007. Epub ahead of print. PMID: 40089450,. Open source ↗
- Chin HL, Lai PS, Tay SKH. A clinical approach to diagnosis and management of mitochondrial myopathies. Neurotherapeutics. 2024 Jan;21(1):e00304. doi: 10.1016/j.neurot.2023.11.001. Epub 2023 Dec 19. PMID: 38241155; PMCID: PMC10903095. Open source ↗
- Zimmern V, Minassian B. Progressive Myoclonus Epilepsy: A Scoping Review of Diagnostic, Phenotypic and Therapeutic Advances. Genes (Basel). 2024 Jan 27;15(2):171. doi: 10.3390/genes15020171. PMID: 38397161; PMCID: PMC10888128. Open source ↗
- T.Hiwot, F. D.Porter, T.Bremova-Ertl, et al., “2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C,” Journal of Inherited Metabolic Disease49, no. 3 (2026): e70185, https://doi.org/10.1002/jimd.70185. Open source ↗
- Zimmern V, Minassian B. Progressive Myoclonus Epilepsy: A Scoping Review of Diagnostic, Phenotypic and Therapeutic Advances. Genes (Basel). 2024 Jan 27;15(2):171. doi: 10.3390/genes15020171. PMID: 38397161; PMCID: PMC10888128. Open source ↗
- Bolton SC, Soran V, Marfa MP, Imrie J, Gissen P, Jahnova H, Sharma R, Jones S, Santra S, Crushell E, Stampfer M, Coll MJ, Dawson C, Mathieson T, Green J, Dardis A, Bembi B, Patterson MC, Vanier MT, Geberhiwot T. Clinical disease characteristics of patients with Niemann-Pick Disease Type C: findings from the International Niemann-Pick Disease Registry (INPDR). Orphanet J Rare Dis. 2022 Feb 14;17(1):51. doi: 10.1186/s13023-022-02200-4. PMID: 35164809; PMCID: PMC8842861. Open source ↗
- Evans WR, Hendriksz CJ. Niemann-Pick type C disease - the tip of the iceberg? A review of neuropsychiatric presentation, diagnosis and treatment. BJPsych Bull. 2017 Apr;41(2):109-114. doi: 10.1192/pb.bp.116.054072. PMID: 28400970; PMCID: PMC5376728. Open source ↗
- T.Hiwot, F. D.Porter, T.Bremova-Ertl, et al., “2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C,” Journal of Inherited Metabolic Disease49, no. 3 (2026): e70185, https://doi.org/10.1002/jimd.70185. Open source ↗
Evaluation
How satisfied were you with this case?
1 · Not at all satisfied10 · Extremely satisfied
How useful did you find this activity in enhancing your knowledge and skills for improving patient care in your clinical practice?
To what extent were the stated learning objectives met as a result of this activity?
Overall, how would you rate the quality and content presented by the experts in this activity?
How confident are you in applying the information from this activity to patient care?
Following this activity, do you plan to seek additional information on this topic?
Please indicate your level of agreement with the following statements about this activity:
SA = Strongly agree · A = Agree · N = Neutral · D = Disagree · SD = Strongly disagree
Based on the information presented in the activity, I will:
Will this case change how you manage these patients?
Please specify how:
May we contact you in 45 days for a brief follow-up survey on how this activity affected your practice?
Your certificate
Claim your credit at AKHThe detection and diagnosis of Niemann-Pick disease type C
Learning Objectives — Upon completion of the educational activity, participants should be able to:
• Recognize age-dependent NPC red flags in early childhood, including unexplained splenomegaly, developmental concerns, progressive gait or coordination changes, and cataplexy-like events
• Differentiate NPC from common pediatric mimics
• Apply current diagnostic pathways for suspected pediatric NPC, including appropriate selection and sequencing of biomarker testing and confirmatory genetic evaluation to reduce time to diagnosis
• Evaluate and interpret challenging diagnostic results in pediatric NPC
• Implement practice changes to enable earlier identification and referral, including when to escalate testing, coordinate multidisciplinary evaluation, and initiate longitudinal monitoring to improve outcomes
• Recognize the diagnostic significance of ocular motor abnormalities and understand when their presence should prompt NPC evaluation
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Orakle LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians — AKH Inc., Advancing Knowledge in Healthcare designates this enduring for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support — This activity is supported from an independent medical education grant from Zevra Therapeutics.